Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder

Reis,Henning; Tschirdewahn,Stephan; Szarvas,Tibor; Rübben,Herbert; Werner Schmid,Kurt; Grabellus,Florian

doi:10.3892/ol.2011.394

Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder

Authors:
- Henning Reis
- Stephan Tschirdewahn
- Tibor Szarvas
- Herbert Rübben
- Kurt Werner Schmid
- Florian Grabellus
View Affiliations

Affiliations: Institute of Pathology and Neuropathology, University Hospital of Essen, Essen 45122, Germany, Clinic of Urology, University Hospital of Essen, Essen 45122, Germany
Published online on: August 29, 2011 https://doi.org/10.3892/ol.2011.394
Pages: 1149-1153

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucose Transporter 1 (GLUT1) belongs to the expanding mammalian facilitative glucose transporter family. Elevated GLUT1 protein expression has been observed in the majority of urothelial carcinomas, with various effects on clinicopathological parameters. Whereas malignant cells have an accelerated metabolism with increased energy requirements, the membranous expression of GLUTs is amplified. GLUT1 protein expression was evaluated in urothelial tumours of increasing grade of malignancy, supplemented by a tumour proliferation analysis. Particular attention was paid to non-invasive precursors of urothelial carcinoma. A total of 105 paraffin-embedded samples were classified (normal urothelium, low/high‑grade papillary carcinoma, carcinoma in situ and invasive carcinoma). Grading and staging were conducted using the 1998 ISUP/2004 WHO criteria. The staining intensity of GLUT1 was assessed with a standard immunoreactive score (IRS). The Ki-67 index was assessed by counting positive nuclei in representative urothelial hot spots. Results showed that an increased GLUT1-IRS and mean count of Ki-67-positive cells were significantly associated with an increased grade of malignancy (p<0.0001), particularly in non-invasive tumours. GLUT1-IRS was significantly associated with a Ki-67-labelled proliferative fraction (p<0.0001). No significant association regarding tumour grade or stage was observed within the invasive carcinoma group. GLUT1 protein expression was found to be strongly correlated with increased malignant potential, particularly in non-invasive urothelial carcinomas. The increase of GLUT1 expression may reflect a preinvasive metabolic switch in terms of enhanced cell metabolism concomitant to known genetic alterations. A further increase in invasive carcinomas may be related to hypoxic conditions.

View Figures

View References

1	Lopez-Beltran A and Sauter G: Infiltrating urothelial carcinoma. World Health Organization Classification of Tumours – Tumours of the Urinary System and Male Genital Organs. Eble N: IARC Press; Lyon: pp. 93–109. 2004
2	Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3	Husmann G, Kaatsch P, Katalinic A, Bertz J, Haberland J, Kraywinkel K and Wolf U: 3.17 Bladder. Cancer in Germany 2005/2006 Incidence and Trends. Robert Koch Institute (ed.) and Association of Population-based Cancer Registries in Germany (ed). Robert-Koch-Institut; Berlin: pp. 84–87. 2010
4	Boyle P and Levin B: Bladder cancer. World Health Organization-World Cancer Report 2008. Boyle P and Levin B: IARC Press; Lyon: pp. 444–449. 2008
5	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
6	Macheda ML, Rogers S and Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
7	Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC and Golde DW: Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 100:2842–2848. 1997. View Article : Google Scholar : PubMed/NCBI
8	Gould GW and Holman GD: The glucose transporter family: structure, function and tissue-specific expression. Biochem J. 295:329–341. 1993.PubMed/NCBI
9	Harik SI, Kalaria RN, Whitney PM, Andersson L, Lundahl P, Ledbetter SR and Perry G: Glucose transporters are abundant in cells with ‘occluding’ junctions at the blood-eye barriers. Proc Natl Acad Sci USA. 87:4261–4264. 1990.
10	Younes M, Lechago LV, Somoano JR, Mosharaf M and Lechago J: Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 56:1164–1167. 1996.PubMed/NCBI
11	Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T and Imura H: Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 170:223–230. 1990. View Article : Google Scholar : PubMed/NCBI
12	Brown RS and Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 72:2979–2985. 1993. View Article : Google Scholar : PubMed/NCBI
13	Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T and Hirano H: Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol. 153:798–801. 1995. View Article : Google Scholar : PubMed/NCBI
14	Mellanen P, Minn H, Grenman R and Harkonen P: Expression of glucose transporters in head-and-neck tumors. Int J Cancer. 56:622–629. 1994. View Article : Google Scholar : PubMed/NCBI
15	Chang S, Lee S, Lee C, Kim JI and Kim Y: Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology. 55:448–452. 2000. View Article : Google Scholar : PubMed/NCBI
16	Lee JH, Kim YW and Chang SG: Glucose transporter-1 expression in urothelial papilloma of the bladder. Urol Int. 74:268–271. 2005. View Article : Google Scholar : PubMed/NCBI
17	O’Keeffe MB, Devlin AH, Burns AJ, Gardiner TA, Logan ID, Hirst DG and McKeown SR: Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. Oncol Res. 17:93–101. 2008.PubMed/NCBI
18	Zhou JT, Cai ZM, Li NC and Na YQ: Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof. Zhonghua Yi Xue Za Zhi. 86:1970–1974. 2006.PubMed/NCBI
19	Hoskin PJ, Sibtain A, Daley FM and Wilson GD: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 89:1290–1297. 2003. View Article : Google Scholar : PubMed/NCBI
20	Visca P, Sebastiani V, Pizer ES, Botti C, de Carli P, Filippi S, Monaco S and Alo PL: Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res. 23:335–339. 2003.PubMed/NCBI
21	Younes M, Juarez D, Lechago LV and Lerner SP: Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 21:575–578. 2001.PubMed/NCBI
22	Cheng L, Montironi R, Davidson DD and Lopez-Beltran A: Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 22:S70–S95. 2009. View Article : Google Scholar : PubMed/NCBI
23	Wu XR: Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev. 28:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
24	Lindemann-Docter K and Knuchel R: Update on urothelial carcinoma histopathology. Pathologe. 29:331–338. 2008.PubMed/NCBI
25	Patil VV, Wang ZJ, Sollitto RA, Chuang KW, Konety BR, Hawkins RA and Coakley FV: 18F-FDG PET/CT of transitional cell carcinoma. AJR Am J Roentgenol. 193:W497–W504. 2009. View Article : Google Scholar : PubMed/NCBI
26	Hiyoshi Y, Watanabe M, Imamura Y, Nagai Y, Baba Y, Yoshida N, Toyama E, Hayashi N and Baba H: The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. Oncology. 76:286–292. 2009. View Article : Google Scholar : PubMed/NCBI
27	Usuda K, Sagawa M, Aikawa H, Ueno M, Tanaka M, Machida Y, Zhao XT, Ueda Y, Higashi K and Sakuma T: Correlation between glucose transporter-1 expression and (18)F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer. Gen Thorac Cardiovasc Surg. 58:405–410. 2010. View Article : Google Scholar : PubMed/NCBI